Drug discovery

Chemify's Chemifarm
#AI #Chemify #Drug discovery #Tuberculosis

Chemify receives $1.6 million to advance TB drug discovery 

Scottish tech company Chemify has received $1.6 million from the Gates Foundation to continue the discovery of small molecules for tuberculosis (TB).  Building on a successful collaboration with Lgenia, the expanded project will leverage Chemify’s automated platform to design and synthesise new drug leads, aiming to address one of the world’s most urgent infectious diseases. … Read More

#Business & Investment #News

Lab equipment
#Drug discovery #High throughput screening #Protein chemistry / Proteomics #Webinar

Advancing protein analysis with high-throughput multiplexed fluorescence westerns

In this webinar, hosted by DDW, Bio-Techne unveils the next evolution of the Leo System, expanding the capabilities of Simple Western Technology for high-throughput protein analysis. The Leo System now supports integrated dual fluorescence channels—Near-Infrared (NIR) and Infrared (IR)—alongside chemiluminescence, enabling simultaneous detection of multiple targets within 96 samples in… Read More

Webinar date:
Supported by Bio-Techne
#Webinars

#Biobanking #Biospecimen research #Drug discovery #eBook

Foundations of biospecimen success

Advances in biospecimen science are resolving long-standing challenges that have historically hindered research quality, reproducibility, and innovation across drug discovery, translational medicine, and biobanking. These gaps limit scientific progress because even the most sophisticated analytical tools depend on high-quality, well-characterised human biological specimens. This custom eBook from BioIVT explores the… Read More

#eBooks #Resources

Cell and gene therapy concept
#Cell and gene therapy #Charles River #Drug discovery

Charles River to support companies developing therapeutics 

Charles River Laboratories has announced drug discovery companies will receive scientific and commercial expertise as part of the second cohort of its Cell and Gene Therapy Incubator Program (CIP).  The CIP cohort includes six companies, four of which are advanced therapy developers (CureAge Therapeutics, InterAct Therapeutics, Jaan Biotherapeutics and Kopra Bio) and two enabling technology… Read More

#News

#Autoimmune disease #Drug discovery #Lipidomics #Metabolomics #Precision medicine #Webinar

Webinar: Discover untargeted metabolomics and lipidomics approaches

This webinar, hosted by DDW and supported by Evotec, introduces untargeted metabolomics and lipidomics analyses, which are designed to accelerate research in complex biological systems. The webinar begins with an overview of the principles behind untargeted approaches, highlighting their importance in capturing a comprehensive molecular snapshot without prior assumptions. Read More

Webinar date:
Supported by Evotec
#News

Artificial intelligence
#AI #Drug discovery #Gene synthesis #Synthetic biology

How AI is transforming gene synthesis and genome engineering 

Ajay Gannerkote, President, Integrated DNA Technologies examines how AI is helping to advance the drug discovery landscape. In the past decade, few fields in biotechnology have evolved as dramatically as gene synthesis and genome engineering.  The evolution of digital technologies, particularly the advent of artificial intelligence (AI), has resulted in a… Read More

#Exclusive Content

#Artificial intelligence (AI) #Drug discovery

From concept to impact: How AI agents and scientific models are accelerating biotech innovation – custom webinar with Benchling Dec 2025

AI has reached a turning point in biotech. Real-world scientific agents are beginning to automate the repetitive tasks that slow down research, and transform how we think about extracting insights from scientific data.    In this webinar, hosted by DDW and supported by Benchling, we will learn how organisations can… Read More

#Webinars

#AI #Drug discovery #Immune cells

AI-generated antibodies tolerated by human immune cells 

AI-generated antibodies have been tolerated by human immune cells, drug discovery company Latent Labs has announced.  The antibody designs, generated by Latent Labs’ AI platform, reportedly displayed drug-like properties, including low ex vivo immunogenicity.   Latent Labs hopes its platform, built on its Latent-X2 model, could significantly shorten… Read More

#News

#AI #Drug discovery #Electronic Lab Notebooks (ELN) #Generative AI #Large language model (LLM)

Why we need to talk about third-generation ELNs 

DDW Editor Reece Armstrong provides a sponsored interview with Rob Brown, PhD, Head of the scientific office at Sapio Sciences.  Electronic lab notebooks (ELNs) have served as essential tools in researchers’ arsenals for decades. But as technology has advanced and the demands of drug discovery and development have grown, the… Read More

#Exclusive Content

Microscope
#Biobanking #Biospecimen research #Drug discovery #eBook

eBook: Foundations of biospecimen success

Advances in biospecimen science are resolving long-standing challenges that have historically hindered research quality, reproducibility, and innovation across drug discovery, translational medicine, and biobanking. These gaps limit scientific progress because even the most sophisticated analytical tools depend on high-quality, well-characterised human biological specimens. This custom eBook from BioIVT explores the… Read More

#News

#DDW Turning Science into Business Symposium #Drug discovery #Events

Watch drug discovery experts at DDW Turning Science into Business Symposium

The on-demand version of the DDW Turning Science into Business Symposium is available to watch now!  The event, which took place at The Francis Crick Institute on 4 November, features talks covering aspects of drug discovery including AI, oncology, CRISPR, neuroscience and more.  It… Read More

#News

Novartis head office
#AI #Drug discovery #Novartis

Relation and Novartis to advance atopic disease therapeutics 

UK biopharmaceutical company Relation has partnered with Novartis to advance therapeutics for atopic diseases.  The collaboration will pair Relation’s AI-powered drug discovery platform and human data generation capabilities with Novartis’s expertise in immuno-dermatology to identify, validate, and advance potential first-in-class targets in atopic diseases driven by immune dysregulation.  Under the terms of the agreement, Relation will… Read More

#Business & Investment #News

Great British Pounds, Investment
#ABPI #Drug discovery #UK #UK economy

UK payment rate for new medicines drops to 14.5% in 2026  

The 2026 payment rate for newer medicines under the Voluntary Scheme for Branded Medicines Pricing and Access (VPAG) will be 14.5%, down from a record 22.5% in 2025, the UK government has announced.   This news follows the recent announcement of the UK-US trade agreement… Read More

#News

Biomarkers concept
#Autoimmune disease #Drug discovery #Lipidomics #Metabolomics #Precision medicine #Webinar

Webinar: Accelerate your research in complex biological systems

This webinar, hosted by DDW and supported by Evotec, introduces untargeted metabolomics and lipidomics analyses, which are designed to accelerate research in complex biological systems. The webinar begins with an overview of the principles behind untargeted approaches, highlighting their importance in capturing a comprehensive molecular snapshot without prior assumptions. Read More

Webinar date:
Supported by Evotec
#News

Stem cells
#Assays #Drug development #Drug discovery #iPSC-derived cells #Neuroscience

Technical Guide: Introducing the Brain-Chip R1

A new Technical Guide is now available from Emulate entitled ‘Characterization of the Brain-Chip R1: A First-in-Class, Isogenic Model of the Human Neurovascular Unit‘. Key highlights: Incorporates five iPSC-derived cell types, including proprietary BMECs that exhibit a physiologically relevant brain microvascular endothelial-like phenotype Maintains resting-state glia and a tight,… Read More

#News

#Assays #Drug development #Drug discovery #iPSC-derived cells #Neuroscience

Introducing the Brain-Chip R1: A new era for human-relevant BBB & NVU research

Key highlights: Incorporates five iPSC-derived cell types, including proprietary BMECs that exhibit a physiologically relevant brain microvascular endothelial-like phenotype Maintains resting-state glia and a tight, stable barrier throughout a four-day experimental window Features a streamlined, 12-day direct-to-chip workflow with no pre-plating or expansion steps, enabling robust and reproducible performance… Read More

#Resources #Technical Notes